GSK (LON:GSK) Earns “Hold” Rating from Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reiterated by Deutsche Bank Aktiengesellschaft in a research note issued to investors on Tuesday, Digital Look reports. They presently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential upside of 9.17% from the stock’s current price.

A number of other brokerages have also commented on GSK. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a research note on Wednesday, July 29th. Berenberg Bank lifted their target price on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a report on Tuesday, September 8th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Stock Performance

Shares of GSK stock traded down GBX 24 during trading on Tuesday, hitting GBX 1,832. 2,147,000,000 shares of the company’s stock traded hands, compared to its average volume of 24,171,396. GSK has a 1 year low of GBX 1,590.50 and a 1 year high of GBX 2,282. The business has a 50-day simple moving average of GBX 1,884.73 and a 200-day simple moving average of GBX 1,943.77. The stock has a market capitalization of £73.41 billion, a P/E ratio of 15.55, a PEG ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.

GSK (LON:GSK) last issued its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, analysts forecast that GSK will post 175.980975 EPS for the current year.

Insiders Place Their Bets

In related news, insider Jonathan Symonds bought 1,500 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal purchased 637 shares of the business’s stock in a transaction on Friday, September 18th. The shares were bought at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Over the last ninety days, insiders purchased 2,144 shares of company stock worth $6,009,566. 0.20% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.